---
company: Aeluma, Inc.
ticker: ALMU
form: 8-K
filed: 2026-09-16
accession: 0001213900-26-100546
source: https://www.sec.gov/Archives/edgar/data/1828805/000121390026100546/
---

# Aeluma (ALMU) earnings release, September 16, 2026

Aeluma, Inc. (ALMU) · Form 8-K, Item 2.02 · Filed 2026-09-16 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1828805/000121390026100546/)

Aeluma Announces Fourth Quarter and Full Fiscal

Year 2026 Financial Results

Signed CHIPS Letter of Intent for up to $30

Million for AI and Advanced Computing

Executed New Strategic Agreement With Sumitomo

Chemical Advanced Technologies to Expand Relationship and Increase Wafer Capacity

GOLETA, CA – September 16, 2026 – Aeluma,

Inc. (NASDAQ: ALMU) (“Aeluma” or the “Company”), a semiconductor company specializing in high-performance, scalable technologies for AI, mobile and consumer, defense and aerospace, and quantum, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2026.

Fiscal 2026 and Subsequent Highlights

Management Commentary

“The AI Datacom opportunity has grown significantly, with some market analysts projecting the Data Center IT Semiconductors and Components market will surpass $1.8 trillion in 2030,” said Jonathan Klamkin, Ph.D., Founder and CEO of Aeluma. “With photonic interconnects being an important part of data center investments, scalable high-speed photodetectors and quantum dot lasers have become the focus of the Company’s near-term product development.”

“After establishing a foundation for commercialization in fiscal 2026 that included more than doubling the size of our team, establishing strategic manufacturing partnerships, and bolstering cash, the Company is transitioning from early-stage R&D Government contracts to a focus on scale and commercialization. To this end, we announced a letter of intent (LOI) with the Department of Commerce CHIPS R&D Office for up to $30 million to accelerate development and commercialization for AI and advanced computing, we established relationships with manufacturing supply chain partners, and we advanced our customer engagements.”

“Fiscal 2027 will focus on technology and product development, and expanding our customer engagements. We are in discussions with several important prospective customers in the

AI datacom industry, negotiating NRE agreements that could support our go-to-market strategy. We will continue to grow our team, we are adding MOCVD wafer production capacity, and we executed an important agreement to expand our relationship with supply chain partner Sumitomo

Chemical Advanced Technologies. We believe it is timely to make these investments given the projected scale of our market opportunities, and our customers are aligned with our strategy. Finally, the CHIPS R&D funding, which is subject to definitive agreement negotiations, could accelerate our commercialization timeline,” concluded Dr. Klamkin.

Fiscal Q4 2026 Financial Results

Full Year 2026 Financial Results

Conference Call and Webcast

Aeluma will host a conference call at 2:00 p.m.

Pacific Time / 5:00 p.m. Eastern Time on September 16, 2026, to discuss the Company’s financial results and business outlook. Interested participants may access the conference call by dialing (877) 317-6789 (domestic) or (412) 317-6789 (international) and referencing “Aeluma.”

A live webcast of the call will be available on the “Investors” section of Aeluma’s website and can also be accessed by clicking here. A replay of the conference call will be available on Aeluma’s website shortly after the call concludes.²

Annual Meeting of Stockholders

Aeluma today announced that its board of directors has established November 19, 2026 as the date of its next annual meeting of stockholders (the “Annual Meeting”). The exact time and virtual attendance details for the Annual Meeting will be specified in a definitive proxy statement, which will be filed with the Securities and Exchange Commission.

The date of the Annual Meeting is more than 30 days before the anniversary of Aeluma’s prior annual meeting of stockholders. Accordingly, stockholders who, in accordance with

Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), desire to present proposals (other than director nominations) for inclusion in Aeluma’s proxy materials relating to the Annual Meeting must follow the procedures provided in Rule 14a-8 and our bylaws. To be timely, such proposals must be delivered to or mailed and received by our corporate secretary on or before the close of business on September 26, 2026, which is a reasonable time before printing and mailing of our proxy materials for the meeting.

Stockholders who intend to propose an item of business for consideration at the Annual Meeting, but not have it included in Aeluma’s proxy statement, or intending to nominate a person for election as a director at the Annual Meeting, must provide timely written notice of such proposal or nomination. To be timely under our bylaws, such notice also must be delivered to or mailed and received by our corporate secretary no later than the close of business on September 26, 2026, and must contain the information specified in our bylaws.

In addition to satisfying the foregoing requirements under our bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the nominees selected by our board of directors also must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act, no later than September 26, 2026.

Non

-

GAAP Financial Measures

This press release includes the following non-GAAP financial measures:

The presentation of these financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with

U.S. generally accepted accounting principles (“GAAP”). We believe that the presentation of these non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to Aeluma’s... (truncated) results of operations. We believe that these non-GAAP financial measures provide additional insight into Aeluma’s ongoing performance and core operational activities and provide these measures for more consistent and meaningful comparison between periods.

These measures should only be used to evaluate Aeluma’s results of operations in conjunction with the corresponding GAAP measures.

A reconciliation of each non-GAAP financial measure to its most directly comparable financial measure calculated and presented in accordance with GAAP is provided in the financial statements portion of this press release.³

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other securities laws. All statements in this press release that are not historical are forward-looking statements, including, among other things, potential applications and resulting benefits of Aeluma’s technology, timing of development and commercialization of Aeluma’s products, anticipated demand and markets for Aeluma’s products, whether Aeluma or the U.S. Department of Commerce will enter into definitive award documents on acceptable terms, or at all, whether Aeluma will receive or retain any portion of the proposed CHIPS funding, and the potential issuance of Company securities to the U.S. Department of Commerce. These statements are not historical facts but rather are based on Aeluma’s current expectations, estimates, and projections regarding its business, operations, and other similar or related factors. Words such as “anticipate,” “could,” “growing,” “intend,” “may,” “plan,”

“poised,” “potential,” “will,” “would,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. These forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Aeluma’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including

Aeluma’s history of losses and limited operating history, and its ability to achieve or sustain profitability; competitive, technological, and market risks affecting the adoption of Aeluma’s semiconductor and photonics products for AI, high-performance computing, and other target markets; general economic, geopolitical, and supply-chain conditions affecting the semiconductor industry; uncertainty as to whether Aeluma and the U.S. Department of Commerce will establish and execute definitive award documents for the proposed funding on acceptable terms, or at all; uncertainty as to whether, when, and in what amount Aeluma will receive or retain any portion of the proposed funding; the perceived and actual dilutive effects of the proposed issuance of common stock; impacts of an equity stake by the U.S. government in Aeluma, including any related reputational, regulatory, or governance considerations; Aeluma’s ability to satisfy applicable milestones associated with the funding; the risk that anticipated benefits of the proposed funding, including acceleration of commercialization and scaling of Aeluma’s non-InP photonics platform, may not be realized on the timeline anticipated or at all; changes in U.S. government policy, funding priorities, or budgetary constraints that could affect the availability or continuation of CHIPS programs; and other risks described in Aeluma’s filings with the U.S. Securities and Exchange Commission. Aeluma undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available, except as required by law.

About Aeluma, Inc.

Aeluma (Nasdaq: ALMU) is a transformative semiconductor company specializing in high-performance photonic and electronic technologies that scale. The company’s proprietary platform combines compound semiconductors with scalable manufacturing used for mass market microelectronics to enable volume production and large-scale integration. Applications for Aeluma’s technology include mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum.

Headquartered in Goleta, California, Aeluma operates state-of-the-art R&D and manufacturing capabilities for semiconductor wafer production, quick-turn chip fabrication, rapid prototyping, test and validation. Aeluma also partners with production-scale fabrication foundries, packaging, and integration companies. For more information, visit www.aeluma.com.

Company:

Aeluma, Inc.

(805) 351-2707 info@aeluma.com

Investor Contact:

Financial Profiles, Inc.

Moira Conlon and Donni Case

(310) 622-8224 ir@aeluma.com⁴

Aeluma, Inc. and Subsidiary

Condensed Consolidated Balance Sheets⁵

Aeluma, Inc. and Subsidiary

Condensed Consolidated Statements of Operations⁶

Aeluma, Inc. and Subsidiary

Condensed Consolidated Statements of Cash Flows⁷

Aeluma, Inc. and Subsidiary

Reconciliation of GAAP and Non-GAAP Financial

Measures (unaudited)⁸

## Financial statements

### Income Statement (Twelve Months Ended — Condensed Consolidated Statements of Operations ($ in thousands, except per share data))

| | Three Months Ended (unaudited) – June 30, 2026 | Three Months Ended (unaudited) – March 31, 2026 | Three Months Ended (unaudited) – June 30, 2025 | Twelve Months Ended – June 30, 2026 | Twelve Months Ended – June 30, 2025 |
|---|---:|---:|---:|---:|---:|
| Revenue | 582 | 1,222 | 1,317 | 4,461 | 4,665 |
| Operating expenses: | Cost of revenue | 433 | 836 | 779 | 2,889 | 1,884 |
| Operating expenses: | Research and development | 2,274 | 882 | 165 | 4,668 | 1,295 |
| Operating expenses: | General and administrative | 2,247 | 1,629 | 1,342 | 7,090 | 3,628 |
| Operating expenses: | Total operating expenses | 4,954 | 3,347 | 2,286 | 14,647 | 6,807 |
| Operating expenses: | Loss from operations | -4,372 | -2,125 | -969 | -10,186 | -2,142 |
| Other income (expense): | Interest income | 359 | 325 | 110 | 1,027 | 113 |
| Other income (expense): | Amortization of discount on convertible notes |  |  |  |  | -715 |
| Other income (expense): | Changes in fair value of derivative liabilities |  |  |  |  | -278 |
| Other income (expense): | Total other income (expense), net | 359 | 325 | 110 | 1,027 | -880 |
| Other income (expense): | Loss before income tax expense | -4,013 | -1,800 | -859 | -9,159 | -3,022 |
| Other income (expense): | Net loss | -4,013 | -1,800 | -859 | -9,159 | -3,022 |
| Other income (expense): | Net loss per share – basic and diluted | -0.22 | -0.1 | -0.05 | -0.52 | -0.23 |
| Other income (expense): | Weighted average common shares outstanding - basic and diluted | 18,603,331 | 18,061,402 | 15,824,222 | 17,665,755 | 13,168,345 |
| Other income (expense): | Book value per share | 3.06 | 2.22 | 1.13 | 3.06 | 1.13 |

### Income Statement (Three Months Ended — Reconciliation of GAAP and Non-GAAP Financial Measures (unaudited) ($ in thousands, except per share data))

| | Three Months Ended – June 30, 2026 | Three Months Ended – March 31, 2026 | Three Months Ended – June 30, 2025 | Twelve Months Ended – June 30, 2026 | Twelve Months Ended – June 30, 2025 |
|---|---:|---:|---:|---:|---:|
| GAAP net loss | -4,013 | -1,800 | -859 | -9,159 | -3,022 |
| Non-GAAP adjustments: | Stock-based compensation | 1,308 | 1,099 | 744 | 4,519 | 1,893 |
| Non-GAAP adjustments: | Consulting and advisory |  |  | 3 |  | 20 |
| Non-GAAP adjustments: | Amortization of discount on convertible notes |  |  |  |  | 715 |
| Non-GAAP adjustments: | Changes in fair value of derivative liabilities |  |  |  |  | 278 |
| Non-GAAP adjustments: | Total adjustments to GAAP net loss | 1,308 | 1,099 | 747 | 4,519 | 2,906 |
| Non-GAAP adjustments: | Non-GAAP net loss | -2,705 | -701 | -112 | -4,640 | -116 |
| Non-GAAP adjustments: | Depreciation & amortization | 126 | 115 | 109 | 451 | 415 |
| Non-GAAP adjustments: | Interest income | -359 | -325 | -110 | -1,027 | -113 |
| Non-GAAP adjustments: | Adjusted EBITDA | -2,938 | -911 | -113 | -5,216 | 186 |
| Non-GAAP adjustments: | GAAP net loss per share – basic and diluted | -0.22 | -0.1 | -0.05 | -0.52 | -0.23 |
| Non-GAAP adjustments: | Non-GAAP adjustments | 0.07 | 0.06 | 0.04 | 0.26 | 0.22 |
| Non-GAAP adjustments: | Non-GAAP net loss per share – basic and diluted | -0.15 | -0.04 | -0.01 | -0.26 | -0.01 |

### Balance Sheet (June 30, 2026 — Condensed Consolidated Balance Sheets (in thousands))

| | June 30, 2026 | June 30, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 56,006 | 3,628 |
| Current assets: | Certificate of deposit |  | 12,112 |
| Current assets: | Accounts receivable | 340 | 962 |
| Current assets: | Prepaids and other current assets | 965 | 633 |
| Current assets: | Total current assets | 57,311 | 17,335 |
| Property and equipment: | Equipment | 2,338 | 1,692 |
| Property and equipment: | Leasehold improvements | 547 | 547 |
| Property and equipment: | Accumulated depreciation | -1,469 | -1,021 |
| Property and equipment: | Property and equipment, net | 1,416 | 1,218 |
| Property and equipment: | Right of use asset - operating | 1,916 | 836 |
| Property and equipment: | Other assets | 21 | 17 |
| Property and equipment: | Total assets | 60,664 | 19,406 |
| Current liabilities: | Accounts payable | 341 | 361 |
| Current liabilities: | Accrued expenses and other current liabilities | 1,369 | 206 |
| Current liabilities: | Lease liability - operating, current portion | 180 | 138 |
| Current liabilities: | Total current liabilities | 1,890 | 705 |
| Current liabilities: | Lease liability - operating, long-term portion | 1,842 | 803 |
| Current liabilities: | Total liabilities | 3,732 | 1,508 |
| Stockholders’ equity: | Common stock | 2 | 2 |
| Stockholders’ equity: | Additional paid-in capital | 82,735 | 34,542 |
| Stockholders’ equity: | Accumulated deficit | -25,805 | -16,646 |
| Stockholders’ equity: | Total stockholders’ equity | 56,932 | 17,898 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 60,664 | 19,406 |

### Cash Flow (Twelve Months Ended June 30, — Condensed Consolidated Statements of Cash Flows (in thousands))

| | Twelve Months Ended June 30, – 2026 | Twelve Months Ended June 30, – 2025 |
|---|---:|---:|
| Operating activities: | Net loss | -9,159 | -3,022 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Amortization of deferred compensation |  | 20 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Stock-based compensation expense | 4,519 | 1,893 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Depreciation and amortization expense | 451 | 415 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Amortization of discount on convertible notes |  | 715 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Changes in fair value of derivative liabilities |  | 278 |
| Changes in operating assets and liabilities: | Accounts receivable | 622 | -902 |
| Changes in operating assets and liabilities: | Prepaids and other current assets | -332 | -611 |
| Changes in operating assets and liabilities: | Other assets | -7 |  |
| Changes in operating assets and liabilities: | Accounts payable | -20 | 44 |
